The study examines three different treatment combinations: acetylsalicylic acid (also known as aspirin) at a low dose (75 mg) plus prasugrel (10 mg), aspirin alone at a high dose (300 mg), or aspirin alone at a low dose (75 mg). These medications help prevent blood clots from forming in the newly created bypass grafts. The treatment period with these specific combinations lasts for three months, after which all patients continue with low-dose aspirin only.

The research will track how well the bypass grafts remain open over time and monitor for complications such as bleeding, heart attacks, or the need for additional procedures. Patients will be followed for 12 months after their surgery to evaluate the effectiveness and safety of these different medication combinations.

The purpose of the study is to evaluate whether using a lower dose of prasugrel alone is both feasible and safe for these patients after their procedure. Participants in the study will receive the reduced dose of prasugrel as their only antiplatelet medication, which helps prevent blood clots from forming in the arteries.

Throughout the study, researchers will monitor patients for various health outcomes, including complications like bleeding events and heart-related issues. They will also assess how satisfied patients are with the treatment and how well they adhere to the medication regimen.

The research compares single antiplatelet therapy (SAPT) with dual antiplatelet therapy (DAPT). Antiplatelet medications help prevent blood clots from forming. The purpose is to determine if using just one antiplatelet medication is as effective as using two in preventing complications after the procedure, while potentially reducing bleeding risks.

The study will follow patients for 12 months after their procedure to track outcomes such as death from any cause, the need for additional procedures on the treated blood vessel, and heart attacks related to the treated vessel. Quality of life and functional status will be assessed using questionnaires at different timepoints throughout the study.

The purpose of the study is to compare two different approaches to preventing blood clots in these patients. One approach is a very short period of dual antiplatelet therapy (DAPT), which involves taking two medications that help prevent blood clots. This is followed by a single medication called a P2Y12 inhibitor. The study will compare this approach to the standard DAPT, which is usually taken for a longer period. The medications being studied include KARDEGIC (containing d,l-lysine acetylsalicylate), Brilique (ticagrelor), Plavix (clopidogrel), and Efient (prasugrel). The study will also involve a placebo group.

The trial will last for up to one year, during which the safety and effectiveness of the treatments will be monitored. The main goal is to see if the shorter treatment is as good as the standard treatment in terms of overall health benefits, including reducing the risk of death, heart attacks, strokes, and major bleeding. The study will also look at other outcomes, such as the need for additional heart procedures and hospitalizations. The results will help determine the best treatment approach for older patients who have undergone PCI.

The purpose of the study is to assess the safety and effectiveness of this treatment approach compared to the current standard treatment, which involves using a combination of medications to prevent blood clots. The study will follow patients for a period of 15 months to monitor for any major heart or brain events, such as heart attacks or strokes, as well as any significant bleeding events. The trial will also compare the outcomes of using the P2Y12 inhibitor alone for one month, followed by the DOAC alone for a longer period, against the standard treatment that involves multiple medications over several months.

Participants in the study will receive either the new treatment approach or the standard treatment. The study will help determine if the new approach is as safe and effective as the current standard. This research is important for improving treatment options for patients with atrial fibrillation who have undergone PCI, potentially leading to better health outcomes and fewer complications.

The purpose of the study is to determine if adjusting the dosage of Clopidogrel based on a patient’s body weight or Body Mass Index (BMI) can improve treatment outcomes. Patients with low, normal, or high body weight/BMI will be included to see if the medication works better when the dose is tailored to their body size. The study will also compare the effects of Clopidogrel and Prasugrel in patients with high body weight/BMI.

Participants will take the medication orally and will be monitored for changes in their blood’s ability to clot, using a test called VerifyNow. The study will also look at other factors, such as genetic differences that might affect how the medication works, and will track any major health events like heart attacks, strokes, or bleeding. The trial aims to provide insights into optimizing treatment for patients with chronic coronary syndrome based on their individual characteristics.

Participants in the study will be given either the standard treatment or a new treatment strategy involving Lixiana. The study will compare the safety and effectiveness of these treatments by looking at the risk of bleeding and the occurrence of heart-related events like heart attacks or strokes. The study will last for several weeks, with follow-ups to check on the participants’ health and any side effects they might experience.

The trial aims to provide valuable information on how to best manage patients with these heart conditions, ensuring they receive the safest and most effective treatment. The results will help doctors make informed decisions about using Lixiana in patients with atrial fibrillation and heart syndromes, especially after they have had a PCI procedure.

The purpose of the study is to determine if using a personalized approach to choosing these medications, based on a person’s genetic makeup, can improve the effectiveness of the treatment. This involves using a genetic test to guide the selection of the most suitable anti-platelet drug for each patient. The study will compare this personalized approach to the standard treatment, which typically involves using a combination of two anti-platelet drugs. The main focus will be on how well the medications prevent platelets from clumping together, which is measured using a test called the VerifyNow system.

Participants in the study will be randomly assigned to either the personalized treatment group or the standard treatment group. The study will last for about six months, during which time the effectiveness and safety of the treatments will be monitored. This includes checking for any bleeding complications and other heart-related events. The goal is to find out if the personalized approach can provide better protection against blood clots while minimizing the risk of bleeding.